Last reviewed · How we verify
NCT05825937
Non-Invasive Blood Pressure Monitoring
trial testing ClearSight System in Blood Pressure in 62 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | University of Saskatchewan |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 1 June 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- ClearSight System
Conditions studied
- Blood Pressure — all drugs for Blood Pressure →
Sponsor
University of Saskatchewan
Who can join
18 and older, any sex, with Blood Pressure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate an alternative way of continuously measuring blood pressure in patients coming for complex surgery. The investigators will directly compare the speed of set up and accuracy of the new ClearSight monitor to those taken by the arterial line monitor, which is the current gold standard for recording blood pressure measurements.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of the ClearSight™ finger cuff monitor versus invasive arterial blood pressure measurement in elective cardiac surgery patients: a prospective observational study.
Goncin U, Liu KK, Rawlyk B, Dalkilic S, et al · · 2024 · cited 1× · PMID 39317830 · DOI 10.1007/s12630-024-02834-x
Verify or expand the search:
- PubMed search for NCT05825937
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ClearSight System
Trials testing the same drug.
- NCT04752904 — Noninvasive Continuous Blood Pressure Monitoring for Cesarean Delivery · NA · completed
Other recruiting trials for Blood Pressure
Currently open trials in the same condition.
- NCT07070583 — Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure · NA · recruiting
- NCT07396636 — Machine Learning-Assisted Management of Intraoperative Hypotension for Personalized Treatment · recruiting
- NCT06719518 — Performance Evaluation of the ViTrack Continuous Non-invasive Blood Pressure Measurement Device · recruiting
- NCT07319117 — Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure. · NA · recruiting
- NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
Other University of Saskatchewan trials
Trials by the same sponsor.
- NCT07433686 — Saskatoon Berry Juice for Muscle Recovery · NA · not yet recruiting
- NCT07489469 — Effectiveness of an AI Scribe Compared to Routine Templates for Clinical Documentation in Orthopedic Consultations · NA · completed
- NCT06946316 — Dairy vs Plant-based Beverages for Improving Bone Health During Exercise · NA · recruiting
- NCT04276857 — Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer · NA · recruiting
- NCT03401294 — Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05825937 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Saskatchewan
- Last refreshed: 11 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05825937.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing